The Microbiome in the Obesity-Breast Cancer Axis: Diagnostic and Therapeutic Potential

Pathogens. 2023 Nov 29;12(12):1402. doi: 10.3390/pathogens12121402.

Abstract

A growing body of evidence has demonstrated a relationship between the microbiome, adiposity, and cancer development. The microbiome is emerging as an important factor in metabolic disease and cancer pathogenesis. This review aimed to highlight the role of the microbiome in obesity and its association with cancer, with a particular focus on breast cancer. This review discusses how microbiota dysbiosis may contribute to obesity and obesity-related diseases, which are linked to breast cancer. It also explores the potential of the gut microbiome to influence systemic immunity, leading to carcinogenesis via the modulation of immune function. This review underscores the potential use of the microbiome profile as a diagnostic tool and treatment target, with strategies including probiotics, fecal microbiota transplantation, and dietary interventions. However, this emphasizes the need for more research to fully understand the complex relationship between the microbiome, metabolic disorders, and breast cancer. Future studies should focus on elucidating the mechanisms underlying the impact of the microbiome on breast cancer and exploring the potential of the microbiota profile as a biomarker and treatment target.

Keywords: antibiotics; breast; breast cancer; diagnostic; diet; dysbiosis; inflammation; microbiome; obesity; therapeutic.

Publication types

  • Review

Grants and funding

This research received no external funding.